Rafferty Asset Management
ALLO icon

Rafferty Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Rafferty Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702K Buy
337,535
+55,189
+20% +$121K ﹤0.01% 840
2026
Q1 		$689K Buy
+282,346
New +$566K ﹤0.01% 849
2025
Q1 		– Sell
-367,445
Closed -$783K – 1062
2024
Q4 		$783K Buy
367,445
+50,499
+16% +$125K ﹤0.01% 833
2024
Q3 		$887K Sell
316,946
-267,894
-46% -$714K ﹤0.01% 824
2024
Q2 		$1.36M Sell
584,840
-405,863
-41% -$1.2M 0.01% 743
2024
Q1 		$4.43M Buy
990,703
+761,695
+333% +$3.18M 0.02% 500
2023
Q4 		$735K Sell
229,008
-675,395
-75% -$1.92M ﹤0.01% 875
2023
Q3 		$2.87M Buy
904,403
+19,832
+2% +$86.9K 0.02% 513
2023
Q2 		$4.4M Buy
884,571
+207,534
+31% +$1.12M 0.02% 444
2023
Q1 		$3.34M Sell
677,037
-79,471
-11% -$510K 0.02% 483
2022
Q4 		$4.76M Buy
756,508
+296,677
+65% +$2.75M 0.04% 382
2022
Q3 		$4.97M Buy
459,831
+237,972
+107% +$3.23M 0.05% 339
2022
Q2 		$2.53M Sell
221,859
-346,059
-61% -$3.07M 0.02% 418
2022
Q1 		$5.17M Buy
567,918
+272,539
+92% +$2.84M 0.03% 386
2021
Q4 		$4.41M Buy
295,379
+164,098
+125% +$2.9M 0.02% 430
2021
Q3 		$3.37M Buy
131,281
+31,338
+31% +$744K 0.02% 416
2021
Q2 		$2.61M Buy
99,943
+13,360
+15% +$381K 0.02% 577
2021
Q1 		$3.06M Buy
86,583
+52,585
+155% +$1.77M 0.02% 483
2020
Q4 		$858K Sell
33,998
-27,279
-45% -$889K 0.01% 545
2020
Q3 		$2.31M Buy
61,277
+38,428
+168% +$1.45M 0.03% 373
2020
Q2 		$978K Buy
+22,849
New +$826K 0.01% 553
2020
Q1 		– Sell
-48,615
Closed -$1.26M – 605
2019
Q4 		$1.26M Sell
48,615
-10,811
-18% -$298K 0.02% 495
2019
Q3 		$1.62M Sell
59,426
-17,057
-22% -$486K 0.03% 437
2019
Q2 		$2.05M Buy
76,483
+21,650
+39% +$603K 0.04% 412
2019
Q1 		$1.58M Buy
+54,833
New +$1.59M 0.03% 458

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Rafferty Asset Management's ALLO Position: Q2 2026 in Review

Rafferty Asset Management increased its Allogene Therapeutics (ALLO) stake by 20% in Q2 2026, buying an estimated $121K and bringing the position to 337,535 shares worth $702K. The position accounts for ﹤0.01% of the portfolio, ranked #840.

Rafferty Asset Management first reported a position in ALLO in Q1 2019 and has held it in 25 quarters since. The position peaked at $5.17M in Q1 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Rafferty Asset Management held 337,535 shares of Allogene Therapeutics worth $702K as of Q2 2026.
  • Rafferty Asset Management bought 55,189 Allogene Therapeutics shares in Q2 2026, an estimated $121K.
  • Allogene Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #840 holding.
  • Rafferty Asset Management first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • Rafferty Asset Management's Allogene Therapeutics position peaked at $5.17M in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.